Recombinant Rat CTNNB1 Protein, His (Fc)-Avi-tagged

• Cat.No.: CTNNB1-1316R
• Product Overview: Recombinant Rat CTNNB1 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Rat
• Tag: His&Fc&Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Ctnnb1 catenin (cadherin associated protein), beta 1 [ Rattus norvegicus ]
• Official Symbol: CTNNB1
• Gene ID: 84353
• mRNA Refseq: NM_053357.2
• Protein Refseq: NP_445809.2
• UniProt ID: Q9WU82

Reviews

03/27/2023

Not only does it provide reliable and consistent results due to its high quality and purity, but it also holds significant value in understanding cellular processes and disease mechanisms.

07/28/2017

the CTNNB1 protein offers numerous advantages in trials and research experiments.

06/24/2016

This commitment to excellence ensures that researchers are provided with the most advanced and reliable tools for their investigations.

Q&As

Is the CTNNB1 protein involved in the progression of pancreatic cancer?

Yes, CTNNB1 is implicated in the development and progression of pancreatic cancer, with its dysregulated activity contributing to tumor growth, invasion, and metastasis.

How is the CTNNB1 protein associated with hepatocellular carcinoma (HCC)?

Mutations in the CTNNB1 gene lead to the stabilization and accumulation of β-catenin, contributing to the development of HCC, making it a potential biomarker for the diagnosis and prognosis of HCC.

How is the CTNNB1 protein linked to the prognosis of gastric cancer patients?

Studies have shown that CTNNB1 expression levels can serve as an independent prognostic factor in gastric cancer, with high CTNNB1 expression correlating with poor patient outcomes.

Are there any targeted therapies specifically aimed at CTNNB1 in cancer treatment?

While there are no direct CTNNB1-targeted therapies available, various drugs targeting the Wnt signaling pathway are being developed and tested, which indirectly impact CTNNB1 activity in cancer cells.

How is the expression of CTNNB1 in breast cancer cells associated with patient survival?

High expression levels of CTNNB1 in breast cancer cells have been linked to poor prognosis and shorter overall survival, indicating its potential as a prognostic marker for breast cancer.